The Library
Global respiratory syncytial virus-associated mortality in young children (RSV GOLD) : a retrospective case series
Tools
Tools
Tools
(2017) Global respiratory syncytial virus-associated mortality in young children (RSV GOLD) : a retrospective case series. The Lancet Global Health, 5 (10). e984-e991. doi:10.1016/s2214-109x(17)30344-3
![[img]](http://wrap.warwick.ac.uk/style/images/fileicons/application_pdf.png) |
PDF
WRAP-global-respiratory-syncytial-virus-mortality-RSV-Nokes-2017.pdf - Published Version Embargoed item. Restricted access to Repository staff only - Requires a PDF viewer. Download (1620Kb) |
|
|
PDF
Corrections.pdf - Unspecified Version - Requires a PDF viewer. Download (30Kb) | Preview |
Official URL: https://doi.org/10.1016/S2214-109X(17)30344-3
Abstract
Respiratory syncytial virus (RSV) infection is an important cause of pneumonia mortality in young children. However, clinical data for fatal RSV infection are scarce. We aimed to identify clinical and socioeconomic characteristics of children aged younger than 5 years with RSV-related mortality using individual patient data.In this retrospective case series, we developed an online questionnaire to obtain individual patient data for clinical and socioeconomic characteristics of children aged younger than 5 years who died with community-acquired RSV infection between Jan 1, 1995, and Oct 31, 2015, through leading research groups for child pneumonia identified through a comprehensive literature search and existing research networks. For the literature search, we searched PubMed for articles published up to Feb 3, 2015, using the key terms "RSV", "respiratory syncytial virus", or "respiratory syncytial viral" combined with "mortality", "fatality", "death", "died", "deaths", or "CFR" for articles published in English. We invited researchers and clinicians identified to participate between Nov 1, 2014, and Oct 31, 2015. We calculated descriptive statistics for all variables.We studied 358 children with RSV-related in-hospital death from 23 countries across the world, with data contributed from 31 research groups. 117 (33%) children were from low-income or lower middle-income countries, 77 (22%) were from upper middle-income countries, and 164 (46%) were from high-income countries. 190 (53%) were male. Data for comorbidities were missing for some children in low-income and middle-income countries. Available data showed that comorbidities were present in at least 33 (28%) children from low-income or lower middle-income countries, 36 (47%) from upper middle-income countries, and 114 (70%) from high-income countries. Median age for RSV-related deaths was 5·0 months (IQR 2·3-11·0) in low-income or lower middle-income countries, 4·0 years (2·0-10·0) in upper middle-income countries, and 7·0 years (3·6-16·8) in high-income countries.This study is the first large case series of children who died with community-acquired RSV infection. A substantial proportion of children with RSV-related death had comorbidities. Our results show that perinatal immunisation strategies for children aged younger than 6 months could have a substantial impact on RSV-related child mortality in low-income and middle-income countries.Bill & Melinda Gates Foundation.
| Item Type: | Journal Article | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Subjects: | R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Divisions: | Faculty of Science > Life Sciences (2010- ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| SWORD Depositor: | Library Publications Router | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Library of Congress Subject Headings (LCSH): | Respiratory syncytial virus, Pneumonia -- Infection , Children -- Diseases -- Prevention, Children -- Mortality | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Journal or Publication Title: | The Lancet Global Health | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Publisher: | The Lancet Publishing Group | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ISSN: | 2214-109X | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Official Date: | 1 October 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Dates: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Volume: | 5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Number: | 10 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Page Range: | e984-e991 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DOI: | 10.1016/s2214-109x(17)30344-3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Status: | Peer Reviewed | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Publication Status: | Published | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Publisher Statement: | ** From Europe PMC via Jisc Publications Router. ** Licence for this article: cc by | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Access rights to Published version: | Open Access | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Description: | Correction to Lancet Glob Health 2017; 5: e984–991. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Funder: | Wellcome Trust (London, England), Bill & Melinda Gates Foundation, Centers for Disease Control and Prevention (U.S.), Janssen Pharmaceutical Ltd., Fogarty International Center, National Institute of Allergy and Infectious Diseases (U.S.) (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (U.S.). Division of Epidemiology, Statistics, and Prevention Research, National Institutes of Health (U.S.) (NIH), Union de banques suisses , UBS Optimus Foundation , National Center for Advancing Translational Sciences (U.S.) (NCATS), Ablynx biopharmaceutical, Novavax (Firm), Mabxience (Firm), Bavarian Nordic, Pfizer Inc., Sanofi Aventis (Firm), Becton Dickinson Diagnostics | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Grant number: | 102975, 203077 (Wellcome Trust (London, England)), PRIME Award to the University Medical Center Utrecht, OPP1148988 (Bill & Melinda Gates Foundation) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RIOXX Funder/Project Grant: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Related URLs: |
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
